TRP_1170x120_3-8-19

Upjohn

Pfizer combines its off-patent drug business with Mylan

Pfizer combines its off-patent drug business with Mylan

NEW YORK— Pfizer and Mylan announced Monday a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of